Neuromyelitis Optica Spectrum Disorder (NMOSD) Panel, CSF; test site SJH
Test Overview
Clinical Utility
Many cases of Neuromyelitis Optica-spectrum disorders (NMOSD) are misdiagnosed as Multiple Sclerosis. As correct diagnosis is critical for prognosis, optimal treatment and prediction of relapse, initial testing for both Aquaporin 4 (AQP4) Antibodies and Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies is strongly recommended for new cases of NMOSD – see separate test listings. AQP4 antibodies are detected in about 80% of patients with NMO. Of these seronegative AQP-4 cases 7% will harbour MOG antibodies. Patients very rarely harbour both antibodies.
Method
Cell-based immunofluorescence assay (IFA)
Result Included
Aquaporin 4 Antibodies; Myelin-Oligodendrocyte Glycoprotein Antibodies (Anti-MOG)
Aliases/Synonyms
Anti-MOG; MOG Antibodies; Neuromyelitis Optica (NMO) Antibodies; Anti-NMO; Anti-Aquaporin 4
Specimen
Volume
Sample Volume
2.0 mL
Minimum Volume
1.0 mL
Collection & Handling
Handling Information
Store and send frozen.
Stability
| Ambient | Refrigerated | Frozen |
|---|---|---|
| 6 hours | 14 days | 60 days |
Performance & Interpretation
Turnaround Time
12 days
Results
-
Aquaporin 4 AntibodiesNegative
Comment
Results of 1+ to 4+ indicate the presence of this autoantibody in increasing titers
-
Myelin-Oligodendrocyte Glycoprotein Antibodies (Anti-MOG)Negative
Comment
Results of 1+ to 4+ indicate the presence of this autoantibody in increasing titers
Referral Location
Canada
Interface & Setup
HL7 Interface Codes
| Order Code | Result Name | Result Codes | Units |
|---|---|---|---|
| NMOG CSF | Anti Aquaporin 4 (NMO) (CSF) | 62781 | |
| Anti MOG (CSF) | 62784 |
Test Version
Last Updated
2019-12-24